🧾 What This Document Is

This is a Definitive Proxy Statement (DEF 14A). Think of it as the official "meeting agenda" and "information packet" that a public company sends to its shareholders before an annual meeting.

👉 Why it exists: To give shareholders the information they need to vote on important company matters, like electing directors and approving executive pay.

What to expect: You'll find details on who is running the board, how the top bosses are paid, and which accounting firm the company wants to hire. The big vote happens at the Annual Meeting on May 20, 2026.

🏢 What The Company Does

👉 In simple terms: Thermo Fisher Scientific is like the world's leading toolbox and partner for scientists. They sell the instruments, chemicals, software, and lab services that researchers, drug companies, and hospitals need to do their work.

Mission: "To enable our customers to make the world healthier, cleaner and safer."
Scale: They have over 120,000 employees and made $44.56 billion in revenue in 2025.
Brands: You'll see names like Thermo Scientific, Applied Biosystems, and Patheon on lab equipment and services worldwide.

💰 2025 Performance Highlights

The CEO's letter kicks off by boasting about a strong year. Here are the headline numbers:

Revenue: Grew 4% to $44.56 billion.
Profit (Adjusted EPS): Grew 5% to $22.87 per share.
Cash Generated: Free cash flow was $6.34 billion.
Money Spent: Deployed about $16.5 billion, mainly on acquisitions and returning cash to shareholders.

👉 Why it matters: These numbers show a large, stable company that's still managing to grow and generate a lot of cash, which is key for funding its strategy and paying dividends.

🚀 Key Moves & Strategy

Management highlights how they executed their three-part growth plan:

High-Impact Innovation: Invested $1.4 billion in R&D to launch new products.
Trusted Partner: Deepened customer relationships, especially in drug development, and formed an alliance with OpenAI.
Unparalleled Commercial Engine: Gained market share by leveraging their global scale and digital tools.

A big focus was capital deployment:

M&A: Committed $13 billion to buy companies, including a filtration business from Solventum and, pending, Clario (clinical trial data).
Shareholders: Returned $3.6 billion through share buybacks and dividends.

👥 Board of Directors & Governance

A major purpose of this document is to propose the 11 people who will oversee the company.

The Vote: Shareholders are asked to elect all 11 nominees. One director, James Mullen, is retiring, shrinking the board from 12 to 11 members.
The CEO: Marc N. Casper is both Chairman and CEO, with a strong, independent Lead Director providing oversight.
The Skills: The board highlights a mix of expertise in finance, healthcare, technology, and international business. The filing includes a chart matching directors to these skills.
Refreshment: The board has a policy to retire directors at age 72 and actively refreshes its members. Four new directors have joined since 2020.

👉 Why it matters: You're voting for the stewards of your investment. The company is emphasizing a balanced board with the right skills to guide its strategy.

💼 Executive Compensation ("Say-on-Pay")

This is a critical proposal. The board is asking shareholders for an advisory vote to approve how they pay top executives.

Recent History: In 2025, a significant number of shareholders voted against the pay plan. In response, the Compensation Committee did a major review.
What They Heard: Shareholders wanted to understand the process better and had specific questions about the CEO's 2025 retention grant.
How They Responded: The company engaged with investors representing 56% of shares. Based on feedback, they are not proposing a new retention grant this year and have made other enhancements to the program for transparency and alignment.
CEO Pay Example: For 2025, Marc Casper's total compensation was $22.4 million, with the large majority tied to company performance (stock).

👉 Why it matters: This is your chance to tell the board if you think the executive pay plan is fair and aligns with company performance. The board is signaling it listened to last year's "no" votes.

📦 Financial Oversight & Auditors

Shareholders are asked to ratify (essentially approve) the selection of PricewaterhouseCoopers LLP as the independent auditing firm for 2026. This is a standard, but important, governance check.

The filing also details the strong oversight roles of the Board's committees (Audit, Compensation, etc.) over risks like cybersecurity, AI, and financial controls.

🔮 What's Next & Risks

The company outlines a 2030 Vision and a rolling 5-year plan. Key forward-looking themes include:

Navigating tariffs and U.S. policy changes.
Continuing to integrate Artificial Intelligence into operations and products.
Executing on recent acquisitions.

The Board actively oversees enterprise risk management (ERM), which identifies top strategic, operational, and compliance risks for the company.

⚖️ Big Picture

👍 Strengths & Opportunities:

Market Leader: Unmatched scale and breadth in the life sciences tools sector.
Execution Machine: Proven ability to integrate acquisitions and manage costs via its "PPI Business System."
Mission-Driven Culture: A clear purpose that resonates with customers and employees.

⚠️ Risks & Challenges:

Macro Sensitivity: Business can be impacted by government funding for science, economic cycles, and healthcare policy.
Integration Complexity: Making the most of large, recent acquisitions is always a challenge.
Regulatory & Ethical Scrutiny: As a provider of sensitive technologies, they face oversight on bioethics and compliance.

🧠 The Analogy

Voting on this proxy is like evaluating the crew and flight plan of a massive, long-haul scientific mission. You're not flying the plane (the company), but you're choosing the pilots and navigators (the board), approving the captain's pay package (CEO compensation), and checking that the maintenance crew (auditors) is trustworthy. The document shows you the route they flew last year (performance) and the path they see ahead (strategy).

🧩 Final Takeaway

Thermo Fisher is a powerhouse executing well in a complex world. Your vote this year is particularly important on the "Say-on-Pay" proposal, as the board has actively responded to shareholder concerns from last year. The company is asking for your confidence in its leadership, strategy, and oversight as it pursues its ambitious "2030 Vision."

THERMO FISHER SCIENTIFIC INC. — DEF 14A Filing